Advancements in cell and gene-based therapies drive initiatives to market effective treatments. With increasing demand for cell production and extensive clinical data, a greater emphasis on biomanufacturing is crucial for efficient and scalable production. The surge in demand for these therapies is propelling the growth of cell and gene therapy biomanufacturers, offering opportunities for expansion and market consolidation. In the Asia-Pacific region, rapid growth is observed in the cell and gene therapy biomanufacturing market due to a robust clinical pipeline, increasing developers, and rising target indication groups.
According to the BIS Research market intelligence report, the APAC cell and gene therapy biomanufacturing market was valued at $1.81 billion in 2021 and is expected to reach $8.60 billion by the end of 2031, growing at a CAGR of 17.88% during the forecast period 2022-2031. Regulatory advancements, ongoing research, and collaboration between industry leaders contribute to the growth of the APAC cell and gene therapy biomanufacturing market.
A substantial increase in the target indications for cell and gene therapies drives the APAC cell and gene therapy biomanufacturing market. This increase is creating a growing demand for large-scale biomanufacturing. The entry of new participants into the cell and gene therapy market is boosting the demand for biomanufacturing facilities and equipment. This trend is set to continue over the next decade, sustaining the need for manufacturing infrastructure. Moreover, a robust clinical pipeline contributes to the demand for biomanufacturing infrastructure.
While the market shows strong growth potential, high set-up costs associated with establishing biomanufacturing facilities are a significant restraint.
BIS Research report on the APAC cell and gene therapy biomanufacturing market is segmented based on product, end-user, and country. The consumables are expected to dominate the product segment of the market. Contract manufacturing organizations (CMOs) are expected to be the fastest-growing end-user segment during the forecast period 2022-2031. The segment is expected to grow at a CAGR of 21.07% during the forecast period.
China leads the Asia-Pacific cell and gene therapy biomanufacturing market, as most established companies are located here. The region is expected to reach $2.71 billion in 2031 with a CAGR of 20.04%.
Key industry trends in the APAC cell and gene therapy biomanufacturing market include an increased focus on automation, utilizing artificial intelligence and robotics to improve production efficiency, lower costs, and enhance quality control. Also, businesses are expanding production capacity to meet the growing demand for these therapies, building new plants, and expanding existing facilities. Moreover, closed and variable manufacturing systems are increasingly adopted, which reduce contamination risks and enhance production efficiency.
The APAC cell and gene therapy biomanufacturing market report offers unique selling points (USPs), such as an in-depth competitive analysis of major players, providing a comprehensive overview of the APAC cell and gene therapy biomanufacturing market. It examines the market's economic influence and highlights notable end-user industry advancements. The report conducts a thorough supply chain and pricing analysis. It also delves into the investment landscape, assessing product adoption trends and patents. These features make the report a valuable resource for understanding the APAC cell and gene therapy biomanufacturing market's dynamics and opportunities.
According to BIS principal analyst, Healthcare, "The APAC cell and gene therapy biomanufacturing market is being propelled by the increasing prevalence of diseases like orphan diseases, cancers, metabolic disorders, and autoimmune disorders, along with the growing approval of cell and gene therapies in the region. The market has seen a rise in new entrants and investments in these therapies, boosting the demand for consumables, equipment, and software used in their manufacturing. This trend is anticipated to continue in the foreseeable future, leading to a substantial impact on the global cell and gene therapy biomanufacturing market."
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.
